Sriram Ryali Net Worth

The estimated Net Worth of Sriram Ryali is at least $1.35 Million dollars as of 8 September 2023. Mr. Ryali owns over 11,650 units of Eiger BioPharmaceuticals Inc stock worth over $212,936 and over the last 6 years he sold EIGR stock worth over $12,690. In addition, he makes $1,124,190 as Chief Financial Officer at Eiger BioPharmaceuticals Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Mr. Ryali EIGR stock SEC Form 4 insiders trading

Sriram has made over 3 trades of the Eiger BioPharmaceuticals Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he bought 11,650 units of EIGR stock worth $19,805 on 8 September 2023.

The largest trade he's ever made was buying 11,650 units of Eiger BioPharmaceuticals Inc stock on 8 September 2023 worth over $19,805. On average, Sriram trades about 1,264 units every 133 days since 2019. As of 8 September 2023 he still owns at least 123,441 units of Eiger BioPharmaceuticals Inc stock.

You can see the complete history of Mr. Ryali stock trades at the bottom of the page.

Sriram Ryali biography

Sriram Ryali serves as Chief Financial Officer of the Company. He was most recently at Aimmune Therapeutics, Inc., where he was Vice President of Finance, responsible for building and leading the finance department from Aimmune’s 2015 initial public offering, and subsequently was a key executive involved in operational preparation for product approval. Previously, Mr. Ryali led U.S. Financial Planning and Analysis at Jazz Pharmaceuticals plc and was Head of Corporate Finance at Onyx Pharmaceuticals, Inc., until the company was acquired by Amgen, Inc. in 2013. Following the acquisition, Mr. Ryali continued as Head of R&D, Technical Operations, and Medical Affairs Finance at Onyx. Mr. Ryali began his career in biopharmaceutical companies at Amgen Inc., where he held positions of increasing responsibility in the finance organization. Mr. Ryali earned a BA from UCLA with a double major in Economics and Microbiology, Immunology & Molecular Genetics and an MBA from UCLA Anderson School of Management.

What is the salary of Sriram Ryali?

As the Chief Financial Officer of Eiger BioPharmaceuticals Inc, the total compensation of Sriram Ryali at Eiger BioPharmaceuticals Inc is $1,124,190. There are 3 executives at Eiger BioPharmaceuticals Inc getting paid more, with David Cory having the highest compensation of $2,871,850.

How old is Sriram Ryali?

Sriram Ryali is 39, he's been the Chief Financial Officer of Eiger BioPharmaceuticals Inc since 2018. There are 18 older and no younger executives at Eiger BioPharmaceuticals Inc. The oldest executive at Eiger BioPharmaceuticals Inc is Dr. Colin Hislop, 63, who is the Sr. VP of Clinical & Devel. Operations.

What's Sriram Ryali's mailing address?

Sriram's mailing address filed with the SEC is C/O CODEXIS, INC., 200 PENOBSCOT DRIVE, REDWOOD CITY, CA, 94063.

Insiders trading at Eiger BioPharmaceuticals Inc

Over the last 9 years, insiders at Eiger BioPharmaceuticals Inc have traded over $3,017,304 worth of Eiger BioPharmaceuticals Inc stock and bought 780,533 units worth $4,706,203 . The most active insiders traders include Richard A Kayne, Edgar Engleman, and Partners X Lp Inter West Ma.... On average, Eiger BioPharmaceuticals Inc executives and independent directors trade stock every 70 days with the average trade being worth of $47,232. The most recent stock trade was executed by Richard A Kayne on 31 October 2023, trading 278,239 units of EIGR stock currently worth $72,342.

What does Eiger BioPharmaceuticals Inc do?

eiger inc is a research company located in 500 crescent ct ste 300, dallas, texas, united states.

Complete history of Mr. Ryali stock trades at Codexis and Eiger BioPharmaceuticals Inc

Eiger BioPharmaceuticals Inc executives and stock owners

Eiger BioPharmaceuticals Inc executives and other stock owners filed with the SEC include:

• David Cory,
  President, Chief Executive Officer, Director
• David Apelian,
  Director
• Stephana Patton,
  Chief Compliance Officer, General Counsel, Corporate Secretary
• Sriram Ryali,
  Chief Financial Officer
• David A. Cory M.B.A., R.Ph., R.Ph, MBA,
  Bus. Founder, Pres, CEO & Director
• James Shaffer,
  Chief Business Officer
• David A. Cory R.Ph, MBA,
  Bus. Founder, Pres, CEO & Director
• Eldon C. Mayer III, M.B.A.,
  Exec. VP & Chief Commercial Officer
• Sriram Ryali M.B.A.,
  Chief Financial Officer
• Christine Murray,
  Independent Director
• Thomas Dietz,
  Independent Chairman of the Board
• Amit Sachdev,
  Independent Director
• Evan Loh,
  Independent Director
• Eldon Mayer,
  Executive Vice President, Chief Commercial Officer
• Jeffrey Glenn,
  Independent Director
• Dr. Evan Loh,
  CEO of Paratek Pharmaceuticals & Director
• Dr. Jeffrey S. Glenn,
  Founder, Scientific Advisor & Independent Director
• Dr. Stephana E. Patton J.D., Ph.D.,
  Consultant
• Erik Atkisson,
  Gen. Counsel, Corp. Sec. & Chief Compliance Officer
• Dr. Colin Hislop,
  Sr. VP of Clinical & Devel. Operations
• Rich Franco M.B.A.,
  Sr. VP & Progeria Program Lead
• Dr. Ingrid C. Choong,
  Sr. VP of Clinical Devel.
• Charles Bramlage,
  Director
• Edgar Engleman,
  Director
• Joanne Quan,
  Chief Medical Officer
• Eduardo Bruno Martins,
  SVP, Liver and Infectious Dise
• Ventures Vi, Llc Vivo Ventu...,
  
• James H Welch,
  Chief Financial Officer
• Nina S Kjellson,
  Director
• Kim Sablich,
  
• Partners X Lp Inter West Ma...,
  
• Ingrid Choong,
  Chief Business Officer
• Erik Atkisson,
  GC & Chief Compliance Officer
• Lisa Kelly Croswell,
  
• James Vollins,
  General Counsel
• Leen Kawas,
  
• Richard A Kayne,